New Prevention Technologies

20 July 2010, AIDS 2010Ebony Johnsson

www.gnpplus.net

At LIVING 2008 Summit

Discussion paper on “Positive Prevention”:• Recognition of current research on NPTs (vaccines, microbicides, PrEP, Tx for Px)• Recommendation to explore role of PLHIV in NPT research and development

2

www.gnpplus.net

NPT Working Group - 1

3

• Convened September 2009• Objectives:

– Support the process of documenting the experiences and perspectives of PLHIV on NPTs;

– Highlight and advocate for opportunities for PLHIV to be involved in NPT R&D;

– Inform regional and national PLHIV networks of developments in the NPT field.

www.gnpplus.net

NPT Working Group – 26 Networks of PLHIV1. APN+2. All-Ukrainian

Network of PLHIV3. GNP+NA4. NEPHAK (Kenya)5. PozFem UK6. RedLa+

4 Partner Organizations1. EATG2. ICW Global3. ITPC/ HIV

Collaborative Fund4. TAC

4

www.gnpplus.net

Four Moderated and Structured Teleconferences

• Research site investigators• Site staff• People living with HIV

www.gnpplus.net

Online discussion forum

www.gnpplus.net

Key discussion points

• Meaningful roles for PLHIV in discussions on HIV prevention research ethics

• Meaningful roles for PLHIV in addressing questions on ARV-based prevention

• Collaboration between treatment and prevention advocates to address ARV-based prevention

• Defining the role(s) of PLHIV in HIV prevention trials

7

www.gnpplus.net

OutputsDiscussion paper: • Exploration of the roles of PLHIV in

Biomedical Prevention Research Toolkit for networks of PLHIV: • New Prevention Tools – What are they? • What is their relevance for PLHIV?Participation and advocacy:• WHO PrEP & ART for Prevention

Consultations (November 2009)• International Microbicides Conference (May

2010)8

www.gnpplus.net

Follow-up: Face-to-Face Consultation

Amsterdam, 5-6 July

Scientific Community

• IAVI• IPM

Advocacy Community

• AVAC• GCM• IRMA

9

NPT Working Group Members

www.gnpplus.net

Discussions• Updates on current HIV

prevention trials• Open and constructive dialogue

about implications of NPT R&D for PLHIV:- Vaccines- Microbicides (Vaginal and Rectal)- PrEP - ART for prevention

www.gnpplus.net

We are developing an advocacy agenda!

• Teleconferences, online discussions and face-to-face consultation will inform our advocacy agenda

• Development and revision process: July 2010 – December 2010

11

www.gnpplus.net

Initial recommendations• Clarify range of Tx and Px linkages and

implications for PLHIV• Develop guidance on ‘risk’ and ‘shared

responsibility’ for PLHIV• Clarify target audiences of NPTs and plans for

access at country-level• Map out what ‘meaningful engagement’ of

PLHIV in clinical trials would look like• Develop clear guidelines for networks of PLHIV

and normative agencies on representation in international consultations and meetings

12

www.gnpplus.net

Learn more!Poster presentation:22 July 2010 12.30 –

14.30Poster number:

THPE0261

13

www.gnpplus.net

Thank you to the NPT Working Group and partners for supporting this programme!

For more information, visit www.gnpplus.net

14